BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gurnari C, Voso MT, Girardi K, Mastronuzzi A, Strocchio L. Acute Promyelocytic Leukemia in Children: A Model of Precision Medicine and Chemotherapy-Free Therapy. Int J Mol Sci 2021;22:E642. [PMID: 33440683 DOI: 10.3390/ijms22020642] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Chin L, Kumana CR, Kwong Y, Gill H. The Development and Clinical Applications of Oral Arsenic Trioxide for Acute Promyelocytic Leukaemia and Other Diseases. Pharmaceutics 2022;14:1945. [DOI: 10.3390/pharmaceutics14091945] [Reference Citation Analysis]
2 Zhao Q, Cheng J, Bian X, Wang C, Xu Y, Ding H, Ren H, Zhang Y, Xu M, Shan C, Yan H, Duan J, Qian D, Huang X. Pharmacokinetics-derived absorbed components responsible for Guizhi-Fuling capsule target PI3K/Akt-Erk to exert an anti-dysmenorrhea effect. J Ethnopharmacol 2022;297:115525. [PMID: 35811027 DOI: 10.1016/j.jep.2022.115525] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Reinhardt D, Antoniou E, Waack K. Pediatric Acute Myeloid Leukemia—Past, Present, and Future. JCM 2022;11:504. [DOI: 10.3390/jcm11030504] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
4 Liu X, Yin W, Widjaya AS, Yang Y, Liu Y, Jiang Y. A practical strategy to subcutaneous administered in-situ gelling co-delivery system of arsenic and retinoic acid for the treatment of acute promyelocytic leukemia. Asian J Pharm Sci 2021;16:633-42. [PMID: 34849168 DOI: 10.1016/j.ajps.2021.07.003] [Reference Citation Analysis]
5 Gurnari C, Divona M, Voso MT. What are the considerations for the pharmacotherapeutic management of acute promyelocytic leukemia in children? Expert Opin Pharmacother 2021;:1-6. [PMID: 34842028 DOI: 10.1080/14656566.2021.2006182] [Reference Citation Analysis]
6 Ferrara F, Molica M, Bernardi M. Drug treatment options for acute promyelocytic leukemia. Expert Opin Pharmacother 2021;:1-11. [PMID: 34348549 DOI: 10.1080/14656566.2021.1961744] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]